EGFR and interstitial lung disease: Besides, EGFR has dual pro-fibrotic and anti-fibrotic effect, and cancer patients treated with EGFR tyrosine kinase inhibitors-monoclonal antibody present an elevated incidence of interstitial lung disease (Osawa et al., 2015).